| 0.3319 -0.018 (-5.23%) | 03-03 16:00 | |||||||||||||
|
|
| Short term |  |
|||
| Mid term |  |
|||
| Targets | 6-month : | 0.52  |
1-year : | 0.61 |
| Resists | First : | 0.44 |
Second : | 0.52 |
| Pivot price | 0.4 |
|||
| Supports | First : | 0.31 |
Second : | 0.26 |
| MAs | MA(5) : | 0.36 |
MA(20) : | 0.4 |
| MA(100) : | 0.61 |
MA(250) : | 0 | |
| MACD | MACD : | -0.1 |
Signal : | -0.1 |
| %K %D | K(14,3) : | 8.1 |
D(3) : | 8 |
| RSI | RSI(14): 28.4 |
|||
| 52-week | High : | 9.5 | Low : | 0.31 |
Price has closed below its short-term moving average. Short-term moving average is currently below mid-term; and below long-term moving average. From the relationship between price and moving averages: This stock is BEARISH in short-term; and BEARISH in mid-long term.[ CUPR ] has closed below the lower bollinger band by 3.1%. Bollinger Bands are 28% narrower than normal. The current width of the bands does not suggest anything about the future direction or movement of prices.
| If tomorrow: | Open lower | Open higher |
| High: | 0.34 - 0.34 | 0.34 - 0.35 |
| Low: | 0.31 - 0.31 | 0.31 - 0.31 |
| Close: | 0.33 - 0.33 | 0.33 - 0.34 |
Cuprina Holdings (Cayman) Limited is a Singapore-based biomedical and biotechnology company dedicated to developing and commercializing innovative products for managing chronic wounds. The company manufactures and distributes medical-grade sterile blowfly larvae bio-dressing products under the MEDIFLY brand, used as a biological debridement tool for chronic wounds. Additionally, Cuprina operates in the health and beauty sectors, offering cosmeceutical products.
Thu, 08 May 2025
Cuprina Holdings Announces Closing of Underwriter’s Over-Allotment Option in Connection with Initial Public Offering - Stock Titan
Fri, 11 Apr 2025
Cuprina Holdings closes $12 million IPO for wound care expansion - Investing.com
Fri, 11 Apr 2025
Healthcare IPO Alert: Cuprina Raises $12M to Transform Chronic Wound Treatment Market - Stock Titan
Thu, 10 Apr 2025
CUPR - Cuprina Holdings (Cayman) Limited Latest Stock News & Market Updates - Stock Titan
| Price to Book Value: P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly. |
Underperform |
| Price to Earnings: PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS). |
Underperform |
| Discounted cash flow: DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows. |
Underperform |
| Return on Assets: ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit. |
Underperform |
| Return on Equity: ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency. |
Underperform |
| Debt to Equity: evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn. |
Underperform |
|
Exchange:
NASDAQ
|
|
|
Sector:
Healthcare
|
|
|
Industry:
Biotechnology
|
|
| Shares Out | 0 (M) |
| Shares Float | 7 (M) |
| Held by Insiders | 7.37e+006 (%) |
| Held by Institutions | 0 (%) |
| Shares Short | 33 (K) |
| Shares Short P.Month | 0 (K) |
| EPS | -2.81e+006 |
| EPS Est Next Qtrly | 0 |
| EPS Est This Year | 0 |
| EPS Est Next Year | 0 |
| Book Value (p.s.) | 0 |
| Profit Margin | 0 % |
| Operating Margin | -8 % |
| Return on Assets (ttm) | 642.9 % |
| Return on Equity (ttm) | -28.5 % |
| Qtrly Rev. Growth | 30330 % |
| Gross Profit (p.s.) | 0 |
| Sales Per Share | 0 |
| EBITDA (p.s.) | 0 |
| Qtrly Earnings Growth | -0.2 % |
| Operating Cash Flow | 0 (M) |
| Levered Free Cash Flow | -9 (M) |
| PE Ratio | -0.01 |
| PEG Ratio | 0 |
| Price to Book value | 0 |
| Price to Sales | 0 |
| Price to Cash Flow | 0 |
| Dividend | 0 |
| Forward Dividend | 55160 |
| Dividend Yield | 0% |
| Dividend Pay Date | Invalid DateTime. |
| Ex-Dividend Date | Invalid DateTime. |
|
|
|
|
|
|
|
|
|